Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Charmi Patel, Dominic Pilon, Laura Morrison, Christopher Holiday, Marie-Hélène Lafeuille, Patrick Lefebvre & Carmela Benson. (2023) Continuity of care among patients newly initiated on second-generation oral or long-acting injectable antipsychotics during a schizophrenia-related inpatient stay. Current Medical Research and Opinion 39:8, pages 1157-1166.
Read now
Read now
Antoine C El Khoury, Charmi Patel, Panagiotis Mavros, Ahong Huang, Li Wang & Richa Bashyal. (2021) Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia. Neuropsychiatric Disease and Treatment 17, pages 3159-3170.
Read now
Read now
Antoine El Khoury, Charmi Patel, Ahong Huang, Li Wang & Richa Bashyal. (2019) Transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate: a real-world analysis among Veterans Health Administration patients with schizophrenia who have had at least one prior hospitalization. Current Medical Research and Opinion 35:12, pages 2159-2168.
Read now
Read now
Jennifer Munday, Mallik Greene, Eunice Chang, Ann Hartry, Tingjian Yan & Michael S. Broder. (2019) Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data. Current Medical Research and Opinion 35:7, pages 1231-1239.
Read now
Read now
Antoine C. El Khoury, Dominic Pilon, Laura Morrison, Nina Shak, Maude Vermette-Laforme, Tony B. Amos, Edward Kim & Patrick Lefebvre. (2019) The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia. Current Medical Research and Opinion 35:3, pages 395-405.
Read now
Read now
Charles Ruetsch, Hyong Un & Heidi C Waters. (2018) Claims-based proxies of patient instability among commercially insured adults with schizophrenia. ClinicoEconomics and Outcomes Research 10, pages 259-267.
Read now
Read now
Tingjian Yan, Mallik Greene, Eunice Chang, Ann Hartry, Maëlys Touya & Michael S. Broder. (2018) All-cause hospitalization and associated costs in patients with schizophrenia or bipolar disorder initiating long-acting injectable antipsychotics. Current Medical Research and Opinion 34:1, pages 41-47.
Read now
Read now
Jason Shafrin, Suepattra G May, Anshu Shrestha, Charles Ruetsch, Nicole Gerlanc, Felicia Forma, Ainslie Hatch, Darius N Lakdawalla & Jean-Pierre Lindenmayer. (2017) Access to credible information on schizophrenia patients’ medication adherence by prescribers can change their treatment strategies: evidence from an online survey of providers. Patient Preference and Adherence 11, pages 1071-1081.
Read now
Read now
Dominic Pilon, Kruti Joshi, Neeta Tandon, Marie-Hélène Lafeuille, Rhiannon L Kamstra, Bruno Emond & Patrick Lefebvre. (2017) Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic. Patient Preference and Adherence 11, pages 619-629.
Read now
Read now
Thomas R. Einarson, Hanna Pudas, Pushpendra Goswami, Kristel van Impe & Basil G. Bereza. (2016) Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland. Journal of Medical Economics 19:2, pages 121-130.
Read now
Read now
Nesrin Dilbaz. (2015) New Targets for the Management of Schizophrenia. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 25:4, pages 407-428.
Read now
Read now
K. Joshi, J. Lin, M. Lingohr-Smith & D. J. Fu. (2015) Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder. Journal of Medical Economics 18:8, pages 629-636.
Read now
Read now
Onur Baser, Lin Xie, Jacqueline Pesa & Mike Durkin. (2015) Healthcare utilization and costs of veterans health administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics. Journal of Medical Economics 18:5, pages 357-365.
Read now
Read now
Luis San, Manuel Serrano, Fernando Cañas, Samuel Leopoldo Romero, Ángeles Sánchez-Cabezudo & Mariano Villar. (2015) Towards a pragmatic and operational definition of relapse in schizophrenia: A Delphi consensus approach. International Journal of Psychiatry in Clinical Practice 19:2, pages 90-98.
Read now
Read now
Sheng-Min Wang, Changsu Han, Soo-Jung Lee, Ashwin A Patkar, Prakash S Masand & Chi-Un Pae. (2014) Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection. Neuropsychiatric Disease and Treatment 10, pages 1605-1611.
Read now
Read now
Articles from other publishers (23)
Habtamu Endashaw Hareru, Kebede Embaye Gezae, Daniel Sisay W/tsadik & Gebremedhin Berhe Gebregergs. (2023) Time to Relapse and Relapse Predictors in Patients with Schizophrenia at Ayder Comprehensive Specialized Hospital, Northern Ethiopia. Mental Illness 2023, pages 1-12.
Crossref
Crossref
Laura MorrisonDee LinCarmela BensonIsabelle GhelerterMaude Vermette-LaformePatrick LefebvreDominic Pilon. (2023) Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate. Journal of Managed Care & Specialty Pharmacy 29:2, pages 161-171.
Crossref
Crossref
Anirban BasuCarmela BensonIbrahim TurkozCharmi PatelPamela BakerBrianne Brown. (2022) Health care resource utilization and costs in patients receiving long-acting injectable vs oral antipsychotics: A comparative analysis from the Disease Recovery Evaluation and Modification (DREaM) study. Journal of Managed Care & Specialty Pharmacy 28:10, pages 1086-1095.
Crossref
Crossref
Xiuru Su, Long Zhao, Yujie Shang, Yingnan Chen, Xiaowen Liu, Xuan Wang, Meihong Xiu, Huijing Yu & Lijun Liu. (2022) Repetitive transcranial magnetic stimulation for psychiatric symptoms in long-term hospitalized veterans with schizophrenia: A randomized double-blind controlled trial. Frontiers in Psychiatry 13.
Crossref
Crossref
Marjanne A. Piena, Natalie Houwing, Carla W. Kraan, Xiaofeng Wang, Heidi Waters, Ruth A. Duffy, Suresh Mallikaarjun & Craig Bennison. (2021) An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia. PharmacoEconomics 40:1, pages 121-131.
Crossref
Crossref
İbrahim Gündoğmuş, Mikail Burak Aydin, Sefa Öz, Azize Beril Taşçi & Özcan Uzun. (2021) Clinical and demographic factors associated with early relapse in patients with schizophrenia: a naturalistic observation study. International Clinical Psychopharmacology 36:6, pages 288-295.
Crossref
Crossref
Dawn I. VelliganMartha SajatovicCynthia SierraJim MintzJulie M. MerkerKristin A. CassidyPatrick Runnels. (2021) A Program to Increase the Appropriate Use of Long-Acting Injectable Antipsychotic Medications in Community Settings. Psychiatric Services 72:9, pages 1012-1017.
Crossref
Crossref
Dominic PilonCharmi PatelMarie-Hélène LafeuilleMaryia ZhdanavaDee LinAurélie Côté-SergentCarmine RossiPatrick LefebvreKruti Joshi. (2021) Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics. Journal of Managed Care & Specialty Pharmacy 27:7, pages 904-914.
Crossref
Crossref
Jörg Mahlich, Kerstin Olbrich, Adrian Wilk, Antonie Wimmer & Claus Wolff-Menzler. (2020) Hospitalization Rates and Therapy Costs of German Schizophrenia Patients Who are Initiated on Long-Acting Injectable Medication: A Mirror-Image Study. Clinical Drug Investigation 40:4, pages 355-375.
Crossref
Crossref
Antoine C. El KhouryDominic PilonLaura MorrisonNina Shak, Amanda LlanezaEdward KimPatrick Lefebvre. (2020) Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia. Journal of Managed Care & Specialty Pharmacy 26:2, pages 176-185.
Crossref
Crossref
Esra Uslu & Kadriye Buldukoglu. (2019) Randomized controlled trial of the effects of nursing care based on a telephone intervention for medication adherence in schizophrenia. Perspectives in Psychiatric Care 56:1, pages 63-71.
Crossref
Crossref
Charmi Patel, Antoine El Khoury, Ahong Huang, Li Wang & Richa Bashyal. (2020) Healthcare Resource Utilization and Costs Among Patients With Schizophrenia Switching From Oral Risperidone/Paliperidone to Once-Monthly Paliperidone Palmitate: A Veterans Health Administration Claims Analysis. Current Therapeutic Research 92, pages 100587.
Crossref
Crossref
Sam Reid & Sagnik Bhattacharyya. (2019) Antipsychotic treatment failure in patients with psychosis and co-morbid cannabis use: A systematic review. Psychiatry Research 280, pages 112523.
Crossref
Crossref
Charmi Patel, Antoine El Khoury, Ahong Huang, Li Wang, Onur Baser & Kruti Joshi. (2019) Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis. Advances in Therapy 36:10, pages 2941-2953.
Crossref
Crossref
丛丛 石. (2019) Effect of Telephone Follow-Up Intervention Pattern on Medication Compliance and Quality of Life of Discharged Patients with Schizophrenia. Advances in Clinical Medicine 09:06, pages 734-738.
Crossref
Crossref
Wallace Breno Barbosa, Juliana de Oliveira Costa, Lívia Lovato Pires de Lemos, Rosângela Maria Gomes, Helian Nunes de Oliveira, Cristina Mariano Ruas, Francisco de Assis Acurcio, Corrado Barbui, Marion Bennie, Brian Godman & Augusto Afonso GuerraJrJr. (2018) Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil. Applied Health Economics and Health Policy 16:5, pages 697-709.
Crossref
Crossref
Lauren M. Hickling, Stefanie Kouvaras, Zaklin Nterian & Rocio Perez-Iglesias. (2018) Non-adherence to antipsychotic medication in first-episode psychosis patients. Psychiatry Research 264, pages 151-154.
Crossref
Crossref
Jeffrey P. Anderson, Zeynep Icten, Veronica Alas, Carmela Benson & Kruti Joshi. (2017) Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations. BMC Psychiatry 17:1.
Crossref
Crossref
Mark Pennington & Paul McCrone. (2017) The Cost of Relapse in Schizophrenia. PharmacoEconomics 35:9, pages 921-936.
Crossref
Crossref
Kruti JoshiJay LinMelissa Lingohr-SmithDong-Jing FuErik Muser. (2016) Treatment Patterns and Antipsychotic Medication Adherence Among Commercially Insured Patients With Schizoaffective Disorder in the United States. Journal of Clinical Psychopharmacology 36:5, pages 429-435.
Crossref
Crossref
A. Ameller & P. Gorwood. (2015) Poids de la comorbidité addictive dans le risque d’observance partielle au traitement médicamenteux et de rechute dans la schizophrénie. L'Encéphale 41:2, pages 174-183.
Crossref
Crossref
Takefumi Suzuki, Hiroyuki Uchida, Hiroyoshi Takeuchi, Takashi Tsuboi, Jinichi Hirano & Masaru Mimura. (2014) A review on schizophrenia and relapse-a quest for user-friendly psychopharmacotherapy. Human Psychopharmacology: Clinical and Experimental 29:5, pages 414-426.
Crossref
Crossref
Mark D Brennan. (2014) Pharmacogenetics of second-generation antipsychotics. Pharmacogenomics 15:6, pages 869-884.
Crossref
Crossref